In concordance with this, we found an antitumor response with high levels of CD8+ T and PD-1+ cells in G4 relative to G3, possibly suggesting that the anti-PD-1 may reinvigorate tumor-specific T cells already stimulated by the ConvitVax. Here, PDCD1 is linked to neoplasm.